Naproxen Tablets

Naproxen is a non-steroidal anti-inflammatory drug (NSAID), the same family as ibuprofen and diclofenac. To understand how it helps gout, it helps to know what gout actually is at the cellular level. Gout is caused by tiny needle-like crystals of monosodium urate — formed when uric acid in the blood reaches saturation point — settling into a joint. The body's immune system reacts to those crystals as if they were a hostile invader, releasing a torrent of inflammatory chemicals that produce the textbook gout flare: sudden severe pain, redness, swelling, warmth, and skin so tender that even a bedsheet feels unbearable. Naproxen works by blocking enzymes called cyclo-oxygenases (COX-1 and COX-2), which the body uses to make prostaglandins — key chemical messengers in the inflammatory cascade. By dampening prostaglandin production, naproxen turns down the inflammatory response, and within a day or two the pain, swelling, and stiffness all start to settle.

Gout is a form of crystal arthritis caused by long-standing elevated uric acid in the blood — a condition called hyperuricaemia. Uric acid is the end-product of breaking down substances called purines, which come partly from our food (red meat, organ meats, shellfish, certain alcohol — especially beer) and partly from the body's own cell turnover. Most people clear uric acid efficiently through the kidneys; some people, due to a combination of genetics, body weight, kidney function, certain medicines (particularly diuretics and low-dose aspirin), and lifestyle factors, don't. Over months or years, uric acid levels rise, crystals start forming in cooler peripheral joints (the big toe is famously the first to suffer because it's the coolest joint in the body), and a flare is eventually triggered — often by something innocuous like a heavy meal, a few drinks, dehydration, surgery, or an illness. So gout isn't a moral failing or just "rich man's disease" — it's a metabolic issue with strong genetic underpinnings, and roughly 1 to 2 per cent of UK adults live with it.

Most people notice some improvement in pain and swelling within 12 to 24 hours of starting naproxen, with substantial relief by 48 hours and full resolution typically over the course of three to seven days. The earlier in the flare you start, the better — gout attacks have a small window where the inflammatory cascade is just getting going, and catching that window with prompt treatment can shorten the attack dramatically. Many people who experience recurrent gout are given a "rescue" supply of naproxen to keep at home, so they can start treatment within hours of the first warning twinges rather than waiting for an appointment.

The usual UK regimen is an initial dose of 750 mg, followed by 250 mg every eight hours until the flare settles — or alternatively, 500 mg twice daily. Whichever schedule is used, it should be taken with food to reduce stomach upset, and continued throughout the flare rather than stopped at the first improvement. Treatment usually runs for about five to seven days, sometimes a few days longer for severe attacks. In older patients, those with previous stomach problems, or anyone on aspirin, a stomach-protecting medicine such as omeprazole or lansoprazole is often prescribed alongside.

Long enough for the inflammation to settle completely, plus a couple of days of safety margin. Stopping too early is one of the most common reasons gout flares come back — the medicine relieves pain quickly, but the underlying inflammation in the joint takes longer to fully resolve, and the crystals haven't gone anywhere. A reasonable rule of thumb is to keep going until the pain, swelling, and tenderness have gone, and then continue for another 24 to 48 hours, before stopping.

Just the attack. This is the single most important point to understand about naproxen and gout, because it shapes how the condition is managed long-term. Naproxen is firefighting: it puts out the immediate flame of inflammation, but it doesn't change the temperature of the room. The room — meaning the elevated uric acid level driving the whole problem — stays exactly the same. As soon as the naproxen is stopped, you're as vulnerable to the next flare as you were before. Long-term prevention requires urate-lowering therapy, most commonly with allopurinol, which slowly brings uric acid levels down over months to a target below the saturation point, allowing existing crystals to dissolve and preventing new ones from forming. Allopurinol and naproxen do completely different jobs and are often used at different points in someone's gout journey rather than against each other.

The most commonly reported are gastrointestinal: stomach pain, indigestion, nausea, and, with longer use or higher doses, peptic ulcers and gastrointestinal bleeding. Older patients, those with a previous ulcer, those on aspirin or anticoagulants, and those on SSRIs (a class of antidepressants) are at particular risk and are usually co-prescribed a proton pump inhibitor for stomach protection. Other side effects include fluid retention and a small rise in blood pressure, headache or dizziness, occasional skin rash, photosensitivity (the skin becoming more sensitive to sun), and rare but serious effects such as kidney injury, heart attack, and stroke — risks that increase with higher doses and longer use. Taken at the right dose for a short course in someone without significant cardiovascular, kidney, or stomach disease, naproxen is generally well tolerated.

Yes — and these are worth flagging because they're the situations where the wrong medicine choice can do real harm. Naproxen should generally be avoided in active peptic ulceration or a recent history of gastrointestinal bleeding, severe heart failure, severe kidney disease (for example an eGFR below 30), known allergy to NSAIDs, and asthma where previous NSAID exposure has triggered wheezing or hives. Caution is also needed if you're on anticoagulants (warfarin, DOACs such as apixaban or rivaroxaban), on lithium or methotrexate, or on the so-called "triple whammy" combination of an ACE inhibitor or ARB, a diuretic, and an NSAID — which can cause acute kidney injury. In any of these situations, alternative gout treatments such as colchicine or a short course of oral steroids are usually preferred, and a clinician will weigh up which fits your overall picture best.

Some combinations are perfectly fine; others need careful thought. The most important interactions are with anticoagulants (significantly increased bleeding risk), low-dose aspirin (increased stomach bleeding risk and reduced cardioprotective effect of aspirin if doses are taken close together), other NSAIDs (additive risks, never combine), SSRIs (increased GI bleeding risk), ACE inhibitors and ARBs (reduced blood pressure effect and increased risk of kidney injury), diuretics (reduced effect and similar renal risks), lithium (raised lithium levels), and methotrexate (raised methotrexate levels). Always tell prescribers about everything you're taking, including herbal remedies and over-the-counter painkillers, so the safest treatment can be chosen.

Alcohol is a well-recognised gout trigger, particularly beer (which is rich in purines from the brewing process) and spirits, while wine in moderation appears to have a smaller effect. Alcohol raises uric acid levels by interfering with how the kidneys clear it and by adding purine load. Cutting back on alcohol — especially during an active flare — is one of the most useful changes you can make. Mixing alcohol with naproxen also increases the risk of stomach irritation and bleeding, so it's generally sensible to avoid alcohol while you're taking the course, both for the gout itself and for the medicine. Hydration matters too: drinking plenty of water through a flare and afterwards helps the kidneys clear uric acid more effectively.

Naproxen is generally avoided in pregnancy, particularly in the third trimester, where it can prematurely close a critical fetal blood vessel called the ductus arteriosus and affect kidney function in the unborn baby. NSAIDs are also generally avoided in the first trimester unless clearly needed, because of a small possible association with miscarriage. Gout in pregnancy is uncommon but does happen, and in those cases the management is led by a specialist using safer alternatives such as paracetamol, low-dose oral steroids, or sometimes intra-articular steroid injections. Naproxen passes into breast milk in small amounts and is generally considered compatible with breastfeeding for short courses, although ibuprofen is often preferred when an NSAID is needed during breastfeeding because it's even less concentrated in milk.

Two other treatments are well established for acute gout. The first is colchicine, an old anti-inflammatory medicine that works by blocking the immune cells (neutrophils) responsible for the gout flare. It's effective and avoids the cardiovascular, renal, and gastric risks of NSAIDs, but it has a narrow therapeutic window — too much causes diarrhoea and other side effects, so doses need to be measured carefully (usually 500 micrograms two to four times a day, reduced if diarrhoea develops). The second is a short course of oral steroids, typically prednisolone 30 to 35 mg daily for five days, which is highly effective and is often the preferred option in patients with significant kidney disease, heart failure, or stomach problems. In some cases, a single corticosteroid injection directly into the affected joint resolves a flare elegantly. The right choice depends on your other medical conditions and is best made with a clinician.

No — and this is one of the most counterintuitive but genuinely important points in gout management. Stopping allopurinol mid-flare causes uric acid levels to swing again, which can prolong or worsen the attack. Modern guidance is unambiguous: if you're already on allopurinol when a flare begins, keep taking it at your usual dose and treat the flare separately with naproxen, colchicine, or steroids. Conversely, you should not start allopurinol for the first time during an acute attack, because the rapid drop in uric acid can shake more crystals loose and trigger further flares. New allopurinol is usually started two to four weeks after a flare has fully settled, often with a low-dose NSAID or colchicine "umbrella" for the first few months to cushion the body through the transition.

Long-term prevention rests on two pillars: lifestyle changes and, in most people with recurrent gout, urate-lowering medication. Lifestyle measures include reducing intake of high-purine foods (red meat, offal, certain seafood including anchovies, sardines, and shellfish), reducing alcohol — particularly beer — losing weight if appropriate, staying well hydrated, and reviewing any medicines that raise uric acid (some diuretics, low-dose aspirin) with your clinician. These measures help, but on their own they typically lower uric acid by only a small amount, so most people with two or more flares a year, tophi (visible urate deposits under the skin), kidney stones, or significant joint damage will benefit from urate-lowering therapy. The most commonly used is allopurinol, started at a low dose and titrated upwards every few weeks until uric acid is below the target (usually under 360 micromol/L, or under 300 in more severe cases). For those who can't tolerate allopurinol, febuxostat is an alternative. Long-term urate-lowering therapy doesn't just prevent flares — over years it can actually dissolve existing crystals and reverse joint damage.

A few situations call for prompt medical review rather than self-management. A first-ever attack of joint pain warrants a proper diagnosis, because conditions that can mimic gout — particularly septic arthritis (a joint infection) and pseudogout (caused by a different crystal, calcium pyrophosphate) — need very different treatment, and missing septic arthritis can be devastating. Any attack accompanied by fever, feeling generally unwell, redness spreading beyond the joint, or affecting multiple joints simultaneously needs urgent assessment. Recurrent flares, attacks that don't respond to naproxen within two or three days, attacks during pregnancy, attacks in someone with significant kidney, heart, or stomach disease, and any visible lumps under the skin (possible tophi) all warrant a clinical review and a discussion about long-term management. Even more importantly, if you're having repeated flares and aren't already on urate-lowering therapy, that's the conversation worth having — naproxen on its own isn't a long-term plan, and the modern aim of gout care is to prevent flares from happening at all rather than to keep firefighting them.